Cell therapy developer Promethera Biosciences has raised $11m that will be inserted into an existing series C round featuring Mitsui, Boehringer Ingelheim and LifeLiver.

Belgium-based cell therapy and regenerative medicine developer Promethera Biosciences closed €10m ($11m) in series C financing on Friday from investors including conglomerate Mitsui, pharmaceutical firm Boehringer Ingelheim and tissue engineering researcher LifeLiver.

Cell Innovation Partners, Vesalius Biocapital, the Government of Wallonia-backed SRIW, Fund+ and SMS Investments also took part in the round, as did Mitsubishi UFJ Capital, the venture capital arm of Mitsubishi UFJ Financial Group.

Mitsui and Boehringer Ingelheim invested through their MGI Global Fund and Boehringer Ingelheim Venture…